Related Experiment Video
Updated: Jun 24, 2025
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
CRISPR in Targeted Therapy and Adoptive T Cell Immunotherapy for Hepatocellular Carcinoma
Fahreddin Palaz1,2, Mehmet Ozsoz3, Ali Zarrinpar4,5
1Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Abstract:
Despite recent therapeutic advancements, outcomes for advanced hepatocellular carcinoma (HCC) remain unsatisfactory, highlighting the need for novel treatments. The CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) gene-editing technology offers innovative treatment approaches, involving genetic manipulation of either cancer cells or adoptive T cells to combat HCC. This review comprehensively assesses the applications of CRISPR systems in HCC treatment, focusing on in vivo targeting of cancer cells and the development of chimeric antigen receptor (CAR) T cells and T cell receptor (TCR)-engineered T cells. We explore potential synergies between CRISPR-based cancer therapeutics and existing treatment options, discussing ongoing clinical trials and the role of CRISPR technology in improving HCC treatment outcomes with advanced safety measures. In summary, this review provides insights into the promising prospects and current challenges of using CRISPR technology in HCC treatment, with the ultimate goal of improving patient outcomes and revolutionizing the landscape of HCC therapeutics.
Insights
CRISPR gene editing offers new ways to treat advanced liver cancer (HCC) by modifying cells. This technology shows promise for improving patient outcomes and overcoming current treatment limitations.
Area of Science:
- Oncology
- Gene Editing
- Immunotherapy
Background:
- Advanced hepatocellular carcinoma (HCC) has poor outcomes despite current therapies.
- Novel treatment strategies are urgently needed for HCC management.
Purpose of the Study:
- To review the applications of CRISPR gene-editing technology in treating HCC.
- To explore CRISPR's role in targeting cancer cells and engineering immune cells for HCC therapy.
Main Methods:
- Comprehensive literature review of CRISPR applications in HCC.
- Focus on in vivo targeting, CAR T-cell, and TCR-engineered T-cell therapies.
- Analysis of potential synergies with existing treatments and clinical trials.
Main Results:
- CRISPR technology enables genetic manipulation of cancer cells and T cells for HCC treatment.
- Applications include in vivo targeting and development of advanced immunotherapies.
- Ongoing trials investigate CRISPR-based strategies for improved HCC outcomes.
Conclusions:
- CRISPR gene editing presents a promising frontier for advanced HCC treatment.
- Challenges and safety considerations are crucial for clinical translation.
- This technology has the potential to revolutionize HCC therapeutics and improve patient survival.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...